FDA
-
-
-
-
-
-
-
MoonLake gets FDA alignment for hidradenitis suppurativa drug filing
-
-
-
-
-
-
-
MoonLake receives FDA fast track designation for sonelokimab PPP treatment
-
-
-
-
-
-
-
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
-
-
-
-
-
-
-
Clear Street Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX)
-
-
-
-
-
-
-
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
-
-
-
-
-
-
-
MoonLake Immunotherapeutics (MLTX) Reports Positive Feedback from FDA and EMA on Regulatory Path for Phase 3 Program of sonelokimab
-
-
-
-
-
-
-
MoonLake Immunotherapeutics (MLTX) to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
-
323,579 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

